New Data From Visudyne® In Minimally Classic(VIM) Trial Confirm Importance Of Lesion Size In The Treatment Of "Wet" AMD
Madrid (ots) - New data from the VIM study presented today at the annual Congress of the European Society of Ophthalmology (SOE) demonstrate that Visudyne® therapy benefited patients with smaller base line lesions* in minimally classic "wet" AMD, a form of AMD previously considered untreatable.1 Visudyne is the ...
mehr